Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma [Yahoo! Finance]
Lisata Therapeutics, Inc. (LSTA)
Company Research
Source: Yahoo! Finance
the treatment of osteosarcoma, a rare type of bone cancer that affects children, adolescents and young adults. Shares of the company were up 8.4% on Mar 21, following the announcement of the news. The RPDD designation is granted by the FDA to medicines that treat serious or life-threatening diseases, usually affecting less than 200,000 children in the United States of all ages. Upon potential approval for LSTA1 by the FDA, the company may become eligible to receive a priority review voucher (“PRV”). This PRV can be used either by LSTA in a subsequent marketing application filed with the FDA for a different product or may even be sold to any other third party to boost cash reserves. LSTA1 is an investigational drug that allows co-administered or tethered anti-cancer drugs to better penetrate solid tumors by activating a novel uptake pathway. The candidate has exhibited the potential to improve the tumor environment, thereby making tumors more responsive to immunotherapy. Shares o
Show less
Read more
Impact Snapshot
Event Time:
LSTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LSTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LSTA alerts
High impacting Lisata Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LSTA
News
- Lisata Therapeutics, Inc. (NASDAQ: LSTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors [Yahoo! Finance]Yahoo! Finance
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma [Yahoo! Finance]Yahoo! Finance
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewswire
- Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma [Yahoo! Finance]Yahoo! Finance
LSTA
Earnings
- 5/9/23 - Beat
LSTA
Sec Filings
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- 4/24/24 - Form 3
- LSTA's page on the SEC website